Xiangxue Buys China, Singapore Rights To Kinex Brain Tumor Drug
This article was originally published in PharmAsia News
Executive Summary
China’s Xiangxue Pharmaceuticals gains China and Singapore marketing rights from U.S.-based Kinex Pharmaceuticals for the KXO2 drug for treating brain tumors.